Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries-Reference-Cited by-同舟云学术

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries

Published:2021-05-13 Issue:12 Volume:10 Page:3862-3872
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Guha Avirup¹^ORCID,Jain Prantesh²,Fradley Michael G.³,Lenihan Daniel⁴,Gutierrez Jahir M.⁵,Jain Chhavi⁶,Lima Marcos²,Barnholtz‐Sloan Jill S.⁷^ORCID,Oliveira Guilherme H.⁸,Dowlati Afshin²^ORCID,Al‐Kindi Sadeer¹

Affiliation:

1. Harrington Heart and Vascular InstituteUniversity HospitalsCase Western Reserve University Cleveland OH USA

2. Division of Hematology and Medical Oncology University Hospitals Cleveland Medical CenterSeidman Cancer Center at Case Comprehensive Cancer CenterCase Western Reserve University Cleveland OH USA

3. Cardio‐Oncology Program Division of Cardiology University of Pennsylvania Philadelphia PA USA

4. Cardio‐Oncology Center of Excellence Division of Cardiology Washington University in St Louis St. Louis MO USA

5. Layer6 Inc. Toronto Canada

6. Lerner Research InstituteCleveland ClinicCase Comprehensive Cancer Center Cleveland OH USA

7. Department of Population and Quantitative Health Sciences Case Comprehensive Cancer Center Case Western Reserve University School of Medicine Cleveland OH USA

8. Division of Cardiovascular Sciences Cardio‐Oncology Program University of South FloridaTampa General Hospital and Moffitt Cancer Center Tampa FL USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3938

Reference32 articles.

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

3. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

5. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib;Cancers;2024-08-23

2. Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis;Frontiers in Immunology;2024-06-24

3. Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?;International Journal of Drug Discovery and Pharmacology;2024-05-23

4. Cardiovascular disease and lung cancer;Frontiers in Oncology;2024-02-12

5. Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database;Biomedicines;2023-08-20